Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  8-K
Filing Date:  5/31/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.51  
Change: 
0.01 (0.40%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$376.33M
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe.
Register for a Free Trial and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01 Entry into a Material Definitive Agreement.
    SECTION 3 SECURITIES AND TRADING MARKETS
      Item 3.03 Material Modification to Rights of Security Holders.
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.03 Amendments to Articles of Incorporation or Bylaws; ...
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 1.1
  EXHIBIT 3.1
  EXHIBIT 4.1
  EXHIBIT 4.2
  EXHIBIT 4.3
  EXHIBIT 5.1
  EXHIBIT 10.1
  EXHIBIT 99.1